A predictive computational platform for optimizing the design of bioartificial pancreas devices
Name:
s41467-022-33760-5.pdf
Size:
6.399Mb
Format:
PDF
Description:
Final Published Version
Author
Ernst, A.U.Wang, L.-H.
Worland, S.C.
Marfil-Garza, B.A.
Wang, X.
Liu, W.
Chiu, A.
Kin, T.
O’Gorman, D.
Steinschneider, S.
Datta, A.K.
Papas, K.K.
James Shapiro, A.M.
Ma, M.
Affiliation
Department of Surgery, University of ArizonaIssue Date
2022
Metadata
Show full item recordPublisher
Nature ResearchCitation
Ernst, A. U., Wang, L.-H., Worland, S. C., Marfil-Garza, B. A., Wang, X., Liu, W., Chiu, A., Kin, T., O’Gorman, D., Steinschneider, S., Datta, A. K., Papas, K. K., James Shapiro, A. M., & Ma, M. (2022). A predictive computational platform for optimizing the design of bioartificial pancreas devices. Nature Communications, 13(1).Journal
Nature CommunicationsRights
Copyright © The Author(s) 2022. This article is licensed under a Creative Commons Attribution 4.0 International License.Collection Information
This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.Abstract
The delivery of encapsulated islets or stem cell-derived insulin-producing cells (i.e., bioartificial pancreas devices) may achieve a functional cure for type 1 diabetes, but their efficacy is limited by mass transport constraints. Modeling such constraints is thus desirable, but previous efforts invoke simplifications which limit the utility of their insights. Herein, we present a computational platform for investigating the therapeutic capacity of generic and user-programmable bioartificial pancreas devices, which accounts for highly influential stochastic properties including the size distribution and random localization of the cells. We first apply the platform in a study which finds that endogenous islet size distribution variance significantly influences device potency. Then we pursue optimizations, determining ideal device structures and estimates of the curative cell dose. Finally, we propose a new, device-specific islet equivalence conversion table, and develop a surrogate machine learning model, hosted on a web application, to rapidly produce these coefficients for user-defined devices. © 2022, The Author(s).Note
Open access journalISSN
2041-1723PubMed ID
36229614Version
Final published versionae974a485f413a2113503eed53cd6c53
10.1038/s41467-022-33760-5
Scopus Count
Collections
Except where otherwise noted, this item's license is described as Copyright © The Author(s) 2022. This article is licensed under a Creative Commons Attribution 4.0 International License.
Related articles
- Biocompatibility and immunology in the encapsulation of islets of Langerhans (bioartificial pancreas).
- Authors: Zekorn TD, Horcher A, Mellert J, Siebers U, Altug T, Emre A, Hahn HJ, Federlin K
- Issue date: 1996 Apr
- Transplantation of macroencapsulated human islets within the bioartificial pancreas βAir to patients with type 1 diabetes mellitus.
- Authors: Carlsson PO, Espes D, Sedigh A, Rotem A, Zimerman B, Grinberg H, Goldman T, Barkai U, Avni Y, Westermark GT, Carlbom L, Ahlström H, Eriksson O, Olerud J, Korsgren O
- Issue date: 2018 Jul
- Macro- or microencapsulation of pig islets to cure type 1 diabetes.
- Authors: Dufrane D, Gianello P
- Issue date: 2012 Dec 21
- Perspectives and Challenges on the Potential Use of Exosomes in Bioartificial Pancreas Engineering.
- Authors: Canning P, Alwan A, Khalil F, Zhang Y, Opara EC
- Issue date: 2022 Oct
- The bioartificial pancreas: progress and challenges.
- Authors: Kizilel S, Garfinkel M, Opara E
- Issue date: 2005 Dec

